Alliances
Infectious disease-focused Vaccitech, which partnered with AstraZeneca and Oxford University on the development and manufacturing of that company’s COVID-19 vaccine, raised $168 million in a Series B financing round.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 16, 2021.
Nearly five years to the day after striking the deal, AVEO Oncology and CANbridge Life Sciences announce the termination of their collaboration and licensing agreement for AVEO’s AV-203.
Two of the biggest drugmakers in the HIV space are teaming up on a combination therapy that has the potential to be a game-changer for patients diagnosed with the dangerous virus for which there is no known cure.
Today, AVEO Oncology announced it had inked a clinical trial collaboration and supply deal with Bristol Myers Squibb to study Fotivda in combination with BMS’s checkpoint inhibitor Opdivo in advanced r/r RCC after previous immunotherapy exposure.
According to the Centers for Disease Control and Prevention, more than 35,000 Americans perish each year from antibiotic-resistant infections, and estimates have AMR claiming the lives of as many as 10 million globally by 2050.
The pair’s lead candidate, TAK-186 (formerly MVC-101), a first-in-class conditionally active T-cell engager, has recently entered the clinic in a Phase I/II study for the treatment of EGFR-expressing solid tumors such as those found in head and neck cancers.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 9, 2021.
Distribution and administration of the Johnson & Johnson vaccine began this week. There is also additional COVID-19 news. Here’s a look.
GE Research selected DNA Script to join a collaboration working on a rapid response, mobile platform to develop on-demand production of nucleic acid-based vaccines and therapies related to biological threats.
PRESS RELEASES